
    
      The participants will be on one week medication after two-weeks observation period.
      Intragastric and intraesophageal multichannel intraluminal impedance-pH (pH-MII) monitoring
      will be performed before and after medication. The pre- and post-treatment data will be
      compared. The safety tests will be performed during study in terms of possible side effects.
    
  